Your browser doesn't support javascript.
loading
Orphan drug clinical development.
Blin, Olivier; Lefebvre, Marie-Noelle; Rascol, Olivier; Micallef, Joëlle.
Afiliación
  • Blin O; Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ, AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France; Orphandev-FCRIN, INSERM, 13005 Marseille, France. Electronic address: olivier.blin@ap-hm.fr.
  • Lefebvre MN; Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ, AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France; Orphandev-FCRIN, INSERM, 13005 Marseille, France.
  • Rascol O; Services de pharmacologie clinique et neurosciences, centre d'investigation clinique CIC 1436, NS-Park/FCRIN network, NeuroToul COEN center, université de Toulouse UPS, CHU de Toulouse, INSERM, 31000 Toulouse, France.
  • Micallef J; Service de pharmacologie clinique et pharmacovigilance, Aix Marseille Univ, AP-HM, INSERM, Inst Neurosci Syst, 13005 Marseille, France.
Therapie ; 75(2): 141-147, 2020 Apr.
Article en En | MEDLINE | ID: mdl-32247678
Clinical development for orphan drugs is extremely demanding but fascinating. There is no single aspect that is really specific to it but instead it gathers most of the hurdles: design, outcomes, recruitment, ethics, cost, probability and predictability for success. To overcome these difficulties, there has to be a great collaboration between academic centers, small and large pharma companies, patients' representatives as well as health authorities to provide support and innovative approaches. The ultimate goal is to give access to patients with unmet medical needs to drugs with a favorable benefit-risk ratio. We review and discuss here the pillars for a successful clinical development for orphan drugs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Producción de Medicamentos sin Interés Comercial / Enfermedades Raras Tipo de estudio: Prognostic_studies Aspecto: Ethics Límite: Humans Idioma: En Revista: Therapie Año: 2020 Tipo del documento: Article Pais de publicación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Producción de Medicamentos sin Interés Comercial / Enfermedades Raras Tipo de estudio: Prognostic_studies Aspecto: Ethics Límite: Humans Idioma: En Revista: Therapie Año: 2020 Tipo del documento: Article Pais de publicación: Francia